The field of psychiatry has seen significant progress in recent years due to worldwide contributions. National productivity, however, in the field of psychiatry is still unclear. In our study, we investigated contributions of individual nations to the field of psychiatry. The Web of Science was used to perform a search from 2011 to 2015 on the subject category “psychiatry”. The total number of articles, citations and the per capita numbers were obtained to analyze the contributions of different countries. In psychiatry journals from 2011 to 2015, 84,760 articles were published worldwide. The most productive world areas were North America, East Asia, Europe and Oceania. The percentage of articles published in high-income countries was 87.77%, middle-income countries published 12.07%, and lower-income published 0.16%. Most articles were published by the United States (32.68%); the United Kingdom was next (8.59%), which was followed by Germany (6.77%), Australia (5.87%), and Canada (4.9%). The country with the highest number of citations (243,394) was the United States. A positive correlation was found between the population/GDP and the number of publications (P < 0.01). Australia ranked the highest when normalized to population size, and the Netherlands and Norway were next. The Netherlands ranked highest, followed by Israel and Australia when adjusted for GDP. The authorship of most of the psychiatry articles was from high-income countries and few papers came from low-income countries. The most productive country was the United States. However, when normalized to population size and GDP, some European and Oceania countries were most productive.

Background: Metabolic imbalance is the common basis of many diseases. As natural isoquinoline alkaloid, berberine (BBR) has shown great promise in regulating glucose and lipids metabolism and treating metabolic disorders. However, the related mechanism still lacks systematic research.Aim: To discuss the role of BBR in the whole body’s systemic metabolic regulation and further explore its therapeutic potential and targets.Method: Based on animal and cell experiments, the mechanism of BBR regulating systemic metabolic processes is reviewed. Potential metabolism-related targets were summarized using Therapeutic Target Database (TTD), DrugBank, GeneCards, and cutting-edge literature. Molecular modeling was applied to explore BBR binding to the potential targets.Results: BBR regulates the whole-body metabolic response including digestive, circulatory, immune, endocrine, and motor systems through adenosine 5’-monophosphate (AMP)-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR), sirtuin (SIRT)1/forkhead box O (FOXO)1/sterol regulatory element-binding protein (SREBP)2, nuclear factor erythroid 2-related factor (Nrf) 2/heme oxygenase (HO)-1, and other signaling pathways. Through these reactions, BBR exerts hypoglycemic, lipid-regulating, anti-inflammatory, anti-oxidation, and immune regulation. Molecular docking results showed that BBR could regulate metabolism targeting FOXO3, Nrf2, NAD(P)H quinone oxidoreductase 1 (NQO1), glutathione peroxidase (Gpx) 4 and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA). Evaluating the target clinical effects, we found that BBR has the therapeutic potential of anti-aging, anti-cancer, relieving kidney disease, regulating the nervous system, and alleviating other chronic diseases.Conclusion: This review elucidates the interaction between potential targets and small molecular metabolites by exploring the mechanism of BBR regulating metabolism. That will help pharmacologists to identify new promising metabolites interacting with these targets.

At present, the relationship between the intake of antioxidants in food and the mortality rate of patients with chronic kidney disease (CKD), especially the association with the mortality rate of specific causes, is not clear. This study included 6379 adult CKD patients from the National Health and Nutrition Examination Survey (2001–2018). Use the Cox proportional hazards model, restricted cubic spline (RCS) model, and stratified and sensitivity analysis to evaluate the relationship between the Composite Dietary Antioxidant Index (CDAI) and mortality in patients with chronic kidney disease. During the follow-up period, 2381 all-cause deaths were recorded, including 719 deaths from cardiovascular disease, 132 deaths from cerebrovascular disease, and 430 deaths from cancer. We found that compared to the lowest quartile of CDAI, the weighted multivariate hazard ratio of participants in the highest quartile was 0.83 (95% confidence interval: 0.72, 0.96) for all-cause mortality, Cardiovascular mortality was 0.91 (95% confidence interval: 0.70, 1.18), Cerebrovascular death was 0.51 (95% confidence interval: 0.24, 1.07), Death due to cancer was 0.64 (95% confidence interval: 0.45, 0.92). RCS analysis shows a non-linear relationship between CDAI and all-cause mortality and cancer mortality. At the same time, there is no non-linear relationship between CDAI and cardiovascular mortality and cerebrovascular mortality. Stratified analysis shows that race and BMI are influencing factors for CDAI-CKD mortality. Sensitivity analysis confirmed the robustness of the results. Our research findings emphasize the potential advantages of an antioxidant diet in reducing the risk of mortality in CKD patients.

Type 2 diabetes mellitus (T2DM), a complex systemic metabolic disorder caused by multiple factors, has been linked to numerous acute and chronic complications. T2DM pathogenesis includes glucotoxicity, lipotoxicity, inflammatory cytokines, and amyloid formation. Within the pancreatic islet microenvironment, the crosstalk among cell types plays a significant role in these pathogenic mechanisms. Islet β cells, macrophages, and endothelial cells, the three primary cell types, engage in intercellular communication under physiological and pathological conditions, critical to maintaining islet homeostasis and promoting the pathological progression of T2DM. This review discusses the interactions between these islet cells, particularly how their crosstalk affects islet function and T2DM development. Additionally, natural products targeting islet cell interactions are discussed as a therapeutic approach for T2DM, along with other personalized treatment options, including exosomes, parasitic therapy, and dietary interventions. Emerging strategies that regulate intercellular signaling and complex crosstalk within the islet microenvironment offer promising avenues for T2DM treatment.